Intercept Pharmaceuticals, Inc. (ICPT): Price and Financial Metrics
ICPT Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for ICPT is -1.87 -- better than just 3.64% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at -6.02 for Intercept Pharmaceuticals Inc; that's greater than it is for only 2.66% of US stocks.
- As for revenue growth, note that ICPT's revenue has grown 24.08% over the past 12 months; that beats the revenue growth of 81.02% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Intercept Pharmaceuticals Inc are LJPC, BNFT, SBBP, AIRG, and PRO.
- ICPT's SEC filings can be seen here. And to visit Intercept Pharmaceuticals Inc's official web site, go to www.interceptpharma.com.
ICPT Stock Price Chart Interactive Chart >
ICPT Price/Volume Stats
| Current price | $20.28 | 52-week high | $95.98 |
| Prev. close | $20.55 | 52-week low | $18.15 |
| Day low | $19.82 | Volume | 5,355,500 |
| Day high | $21.50 | Avg. volume | 1,195,047 |
| 50-day MA | $24.99 | Dividend yield | N/A |
| 200-day MA | $35.04 | Market Cap | 669.56M |
Intercept Pharmaceuticals, Inc. (ICPT) Company Bio
Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic underserved liver diseases. The company was founded in 2002 and is based in New York, New York.
Latest ICPT News From Around the Web
Below are the latest news stories about Intercept Pharmaceuticals Inc that investors may wish to consider to help them evaluate ICPT as an investment opportunity.
Intercept (ICPT) Up 0.4% Since Last Earnings Report: Can It Continue?Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Strong Insider Buying Could Indicate a Bottom in These 2 StocksEvery investor knows that the path toward profits lies in buying low and selling high. That’s a basic precept of any economic trading system. The trick, however, is recognizing when the stock is low enough to buy in. The prime moment to buy is when the stock hits bottom; that will maximize returns when the share price starts to rise again. There are a multitude of possible clues investors can use to find the price bottom; today, we’ll be looking at insider buying trends. Insiders – the corporate officers, board members, and others ‘in the know’ – don’t just manage the companies, they know the details. |
3 Under-the-Radar Growth Stocks With 55% to 106% Upside, According to Wall StreetYou've probably never heard about these fast-paced companies before, but Wall Street believes they can make you a boatload of money. |
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Director Srinivas Akkaraju Acquires 147,000 SharesIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Director Srinivas Akkaraju acquired 147,000 shares of the firm’s stock in a transaction that occurred on Friday, March 12th. The shares were bought at an average cost of $21.29 per share, for a total transaction of $3,129,630.00. Following the purchase, the director now owns 23,121 shares of the company’s stock, valued […] |
The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For TricidaHere's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 25) Apyx Medical Corp (NASDAQ: APYX ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) (announced an $18-million private placement) Bioatla Inc (NASDAQ: BCAB ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) Glaukos Corp (NYSE: GKOS ) Myriad Genetics, Inc. (NASDAQ: MYGN ) Organogenesis Holdings Inc (NASDAQ: ORGO ) Pacira Biosciences Inc (NASDAQ: PCRX ) (announced fourth-quarter results) Pandion Therapeutics Inc (NASDAQ: PAND ) - announced a deal to be bought by Merck & Co., Inc. (NYSE: MRK ) for $1.85 billion Pliant Therapeutics Inc (NASDAQ: PLRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Down In The Dumps (Biot... |
ICPT Price Returns
| 1-mo | -10.66% |
| 3-mo | N/A |
| 6-mo | -33.25% |
| 1-year | -75.05% |
| 3-year | -70.71% |
| 5-year | -86.44% |
| YTD | -17.89% |
| 2020 | -80.07% |
| 2019 | 22.95% |
| 2018 | 72.53% |
| 2017 | -46.23% |
| 2016 | -27.25% |
Continue Researching ICPT
Want to do more research on Intercept Pharmaceuticals Inc's stock and its price? Try the links below:Intercept Pharmaceuticals Inc (ICPT) Stock Price | Nasdaq
Intercept Pharmaceuticals Inc (ICPT) Stock Quote, History and News - Yahoo Finance
Intercept Pharmaceuticals Inc (ICPT) Stock Price and Basic Information | MarketWatch
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...